VACCINEXPAR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.94 USD | +1.54% |
|
+19.68% | -36.18% |
| Apr. 12 | Vaccinex, Inc. announced that it has received $1.75 million in funding | CI |
| Apr. 02 | Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 41.83 | 72.08 | 46.34 | 32.03 | 32.15 | 8.306 |
| Enterprise Value (EV) 1 | 22.1 | 69.3 | 44.95 | 23.83 | 26.24 | 7.018 |
| P/E ratio | -0.64 x | -1.96 x | -1.35 x | -1.34 x | -1.37 x | -0.21 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 57.8 x | 138 x | 74.1 x | 35.6 x | 117 x | 14.6 x |
| EV / Revenue | 30.5 x | 133 x | 71.9 x | 26.5 x | 95.4 x | 12.3 x |
| EV / EBITDA | -0.82 x | -2.18 x | -1.6 x | -1.07 x | -1.33 x | -0.31 x |
| EV / FCF | -1.45 x | -3.7 x | -2.43 x | -1.4 x | -2.22 x | -0.63 x |
| FCF Yield | -68.8% | -27% | -41.1% | -71.6% | -45% | -158% |
| Price to Book | -4.85 x | -2.75 x | -1.74 x | 4.32 x | 6.19 x | -3.59 x |
| Nbr of stocks (in thousands) | 54.6 | 70.8 | 107 | 147 | 238 | 892 |
| Reference price 2 | 765.4 | 1,018 | 434.7 | 218.4 | 135.3 | 9.307 |
| Announcement Date | 3/13/19 | 3/9/20 | 3/31/21 | 3/31/22 | 3/31/23 | 4/2/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.724 | 0.523 | 0.625 | 0.9 | 0.275 | 0.57 |
| EBITDA 1 | -27.06 | -31.77 | -28.02 | -22.32 | -19.7 | -22.77 |
| EBIT 1 | -27.28 | -32.02 | -28.33 | -22.49 | -19.91 | -22.88 |
| Operating Margin | -3,768.09% | -6,121.41% | -4,532.96% | -2,498.89% | -7,238.55% | -4,014.91% |
| Earnings before Tax (EBT) 1 | -29.52 | -31.86 | -28.85 | -22.38 | -19.82 | -20.25 |
| Net income 1 | -29.52 | -31.86 | -28.85 | -22.38 | -19.82 | -20.25 |
| Net margin | -4,077.07% | -6,092.35% | -4,616.16% | -2,486.67% | -7,205.45% | -3,552.81% |
| EPS 2 | -1,187 | -519.5 | -322.5 | -162.9 | -98.70 | -43.68 |
| Free Cash Flow 1 | -15.21 | -18.73 | -18.49 | -17.07 | -11.8 | -11.11 |
| FCF margin | -2,100.5% | -3,581.91% | -2,958.64% | -1,897.21% | -4,291.82% | -1,948.9% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/13/19 | 3/9/20 | 3/31/21 | 3/31/22 | 3/31/23 | 4/2/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 19.7 | 2.78 | 1.39 | 8.2 | 5.91 | 1.29 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -15.2 | -18.7 | -18.5 | -17.1 | -11.8 | -11.1 |
| ROE (net income / shareholders' equity) | -435% | -488% | 1,181% | -933% | -314% | -1,405% |
| ROA (Net income/ Total Assets) | -124% | -150% | -217% | -130% | -140% | -246% |
| Assets 1 | 23.89 | 21.2 | 13.28 | 17.15 | 14.19 | 8.218 |
| Book Value Per Share 2 | -158.0 | -370.0 | -249.0 | 50.50 | 21.90 | -2.590 |
| Cash Flow per Share 2 | 103.0 | 39.20 | 99.40 | 58.60 | 26.90 | 1.720 |
| Capex 1 | 0.24 | 0.08 | 0.29 | 0.03 | 0.1 | 0.07 |
| Capex / Sales | 32.46% | 14.91% | 46.4% | 3.56% | 36% | 11.75% |
| Announcement Date | 3/13/19 | 3/9/20 | 3/31/21 | 3/31/22 | 3/31/23 | 4/2/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- VCNX Stock
- Financials VACCINEXPAR
